Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

20th Sep 2018 07:00

RNS Number : 3323B
Cello Health PLC
20 September 2018
 

20 September 2018

 

Cello Health plc

("Cello" or the "Group")

 

Director/PDMR Shareholding

 

The Group has been notified that, on 19 September 2018, Jane Shirley, Joint CEO of Cello Health Insight and CEO of Cello Health Europe, purchased a total of 20,000 ordinary shares of 10 pence each in the capital of the Company ("Ordinary Shares") for an average price of approximately 135.4 pence per Ordinary Share.

 

Enquiries:

 

Cello Health plc

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Finance Director

Cenkos Securities plc

0207 397 8900

Mark Connelly

Harry Hargreaves

 

Notes to Editors

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

 

 

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jane Shirley

2

Reason for the notification

a)

Position/status

Joint CEO of Cello Health Insight and CEO of Cello Health Europe

b)

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cello Health plc

b)

LEI

2138004TZYGZLWQP7N64

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 10 pence each

Identification code

ISIN: GB00B0310763

b)

Nature of the transaction

Purchase of ordinary shares

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£1.3485

10,000

£1.36

10,000

d)

 

Aggregated information

- Aggregated volume

20,000

- Price

£27,085.00

e)

Date of the transaction

19 September 2018

f)

Place of the transaction

AIMX

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFKCDQDBKBBCD

Related Shares:

CLL.L
FTSE 100 Latest
Value8,809.74
Change53.53